Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Progyny, Inc. filings document public-company reporting for its Nasdaq-listed common stock and its women's health and family building benefits business. Recent Form 8-K reports furnish quarterly and annual financial results, guidance updates, Regulation FD materials, supplemental earnings presentations, and other material-event disclosures.
The company's proxy materials cover annual meeting governance, director and executive compensation, equity award information, and related shareholder voting matters. Other filings address executive employment and compensatory arrangements, as well as a derivative-action settlement notice tied to historical non-employee director compensation practices.
Progyny, Inc.'s president reported a routine equity compensation-related share withholding. On 12/04/2025, 7,977 shares of common stock were withheld at $24.55 per share to pay withholding taxes triggered by the vesting of restricted stock units granted to the officer. After this transaction, the president directly beneficially owned 288,233 Progyny shares.
Progyny, Inc. (PGNY) reported an insider stock sale by its Chief Financial Officer. On 11/17/2025, the CFO sold 21,303 shares of Progyny common stock at a price of $25.50 per share, as shown in Table I of the filing. After this transaction, the CFO beneficially owns 48,358 shares of common stock in a direct capacity.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 15, 2025. These plans allow insiders to systematically sell shares according to preset instructions, helping separate personal liquidity decisions from day-to-day company developments.
Progyny, Inc. (PGNY) director reported an option exercise and a share transfer. On 11/14/2025, the reporting person exercised a stock option for 36,224 shares of common stock at $1.45 per share, paying the exercise price in cash and holding all shares received, with no shares sold in connection with the exercise.
On 11/18/2025, the reporting person transferred 50,265 shares held directly to The Norman C. and Melinda B. Payson Revocable Trust for no consideration, reported as a gift. Following these transactions, the person held common stock directly and also indirectly through the revocable trust and through EVO Eagle, LLC, over which the reporting person shares voting and dispositive power.
Progyny, Inc. (PGNY) disclosed that its Chief Executive Officer and director purchased 79,500 shares of common stock on 11/13/2025. The shares were bought at a weighted average price of $24.288 per share, in multiple trades at prices ranging from $23.73 to $24.52. Following this transaction, the reporting person beneficially owns 680,251 shares directly and an additional share indirectly through PECO ANEVSKI 2020 SD LLC. The filing notes that the purchase was made to offset a tax withholding obligation arising from the net settlement of performance stock units reported the same day.
Progyny, Inc. (PGNY) Form 4: The Executive Chairman and director reported the vesting and settlement of performance stock units. On 11/10/2025, 41,500 PSUs granted on January 1, 2022 were settled into common stock after the Compensation Committee certified performance on 10/31/2025.
To cover withholding taxes upon vesting, 21,286 shares were withheld at $22.37. Following these transactions, the reporting person directly beneficially owns 240,633 shares. These entries reflect equity award settlement and related tax withholding, not an open‑market purchase or sale.
Progyny, Inc. (PGNY) reported an insider equity transaction by its Chief Executive Officer and director. The filing shows the settlement of previously earned performance stock units and related tax withholding.
On November 10, 2025, the reporting person acquired 125,000 shares of common stock at $0 upon settlement of PSUs that vested on October 31, 2025, after certification of performance. On the same date, 63,813 shares were withheld to cover taxes at a price of $22.37 per share. Following these transactions, the filer beneficially owned 600,751 shares directly, plus 1 share held indirectly.
Progyny, Inc. (PGNY) reported stronger Q3 2025 results. Revenue rose to $313.3M from $286.6M, with gross profit of $72.8M. Operating income increased to $21.5M and net income reached $13.9M, or $0.15 diluted EPS. For the first nine months, revenue was $970.3M and net income was $46.0M, reflecting solid year-to-date performance.
Liquidity remained healthy: cash and cash equivalents were $134.0M and marketable securities were $211.2M at quarter end. Operating cash flow for the nine months was $156.0M. The company entered a $200M revolving credit facility maturing in 2030, with no borrowings outstanding, and later authorized a new $200M share repurchase program in November 2025. Total assets were $795.2M and stockholders’ equity was $560.0M. As of October 31, 2025, 86,211,654 common shares were outstanding.
Client base and utilization supported growth: Q3 fertility benefits revenue was $201.9M and pharmacy benefits revenue was $111.4M. The company closed the Benefit Bump acquisition for $10.5M to extend family support offerings.
Progyny (PGNY) furnished an update on its latest results. The company announced financial results for the fiscal quarter ended September 30, 2025 and made these materials available to investors.
A press release and a supplemental earnings presentation were furnished as Exhibit 99.1 and Exhibit 99.2, respectively, and are also accessible via the investor relations site. The information furnished under Items 2.02 and 7.01, including these exhibits, is provided as furnished, not filed.
Progyny, Inc. director and Executive Chairman David J. Schlanger reported a sale of 1,893 shares of Progyny common stock on 10/01/2025 at a price of $21.52 per share. After the transaction, the filing shows he beneficially owns 220,419 shares, held directly. The filing states the shares sold were withheld to cover taxes upon the vesting of restricted stock units granted to the reporting person. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Progyny director and Chief Executive Officer Peter Anevski reported an insider transaction dated 10/01/2025. The Form 4 shows 7,977 shares of Progyny common stock were disposed of at a price of $21.52 per share, with the filer retaining beneficial ownership of 539,564 shares following the transaction. The filing explains the sale resulted from shares withheld to cover taxes on vested restricted stock units and notes the remaining reportable shares are held directly by PECO ANEVSKI 2020 SD LLC. The Form 4 was signed by an attorney-in-fact on 10/02/2025.